Table S1. Demographics, laboratory and genetic data of 95 women with FXI deficiency.

***F11* gene variant†**	**Status††**	**Number**	**Age (years), mean±SD**	**aPTT ratio, mean±SD**	**FXI:C (%), mean±SD**
p.Cys56Arg	Heterozygote	41	45.0 ± 24.1	1.1 ± 0.3	42.3 ± 8.8
	Homozygote	1	44	2	3
p.Glu565Lys	Heterozygote	16	42.0 ± 16.0	1.2 ± 0.3	45.0 ± 10.0
p.Pro538Leu	Heterozygote	15	39.1 ± 17.7	1.2 ± 0.2	51.9 ± 8.0
p.Cys416Tyr	Heterozygote	9	54.1 ± 20.5	1.2 ± 0.4	44.2 ± 18.5
p.Ile426Thr	Heterozygote	2	67.0 ± 25.5	1.3 ± 0.1	34.5 ± 6.4
p.Thr322Ile	Heterozygote	2	51.5 ± 19.1	1.0 ± 0	64.0 ± 2.8
p.Lys536Asn	Heterozygote	1	71	1	22.0
CS081910	Heterozygote	1	89	1	45.0
p.Arg268Cys	Heterozygote	1	68	1	35.0
p.Lys536Asn & p.Cys599Tyr	Compound heterozygote	1	45	2	3.0
p.Cys56Arg & p.Cys416Tyr	Compound heterozygote	1	69	3	2.0
Insertion	Heterozygote	2	22.0 ± 4.2	1.5 ± 0.7	43.0 ± 4.2
Unknown		2	17.0 ± 4.9	1.0 ± 0	60.5 ± 13.4
Total		95		1.4 ± 0.3	43.6 ± 13.3

† Human Genome Variation Society (HGVS) nomenclature.
†† Mutational status: homozygote, heterozygote, compound heterozygote.
aPTT: activated Partial Thromboplastin Time. FXI: factor XI. FXI:C:FXI clotting activity. F11: FXI gene. SD: standard deviation.